Wegovy Dominates GLP-1 Market With New HD Dose, Oral Pill, and NHS Heart Disease Approval

# Wegovy Breakthrough: New High-Dose Approval, NHS Expansion & Pill Wars with Eli Lilly | Obesity Treatment Update 2026 Join veteran health journalist Alexandra Reeves as she unpacks the explosive developments in obesity treatment centered on Novo Nordisk's Wegovy (semaglutide). In this comprehensive episode, discover: **Major Wegovy Developments Covered:** - **ORION Study Results**: New data shows Wegovy's 25mg pill outperforms Eli Lilly's orforglipron (Foundayo) by 3.2 percentage points in weight loss, with 84% patient preference and significantly fewer gastrointestinal side effects - **FDA Approves Wegovy HD**: The new 7.2mg high-dose weekly injection achieves over 20% average weight loss in 72 weeks, with one-third of patients reaching 25% reduction - **NHS England Expansion**: Over 1.2 million cardiovascular disease patients now eligible for Wegovy to reduce heart attack and stroke risks - **First Multi-Month Subscription**: New affordable access through Ro, WeightWatchers, LifeMD, and Hims & Hers, saving patients up to $1,200 annually - **Safety Update**: FDA moves to remove suicidal ideation warnings from GLP-1 receptor agonist labels after finding no clear link **Perfect for:** Healthcare professionals, patients exploring weight loss medications, investors tracking pharmaceutical innovations, and anyone interested in the GLP-1 obesity treatment revolution. **Keywords:** Wegovy, semaglutide, obesity treatment, weight loss medication, GLP-1, Novo Nordisk, Eli Lilly orforglipron, FDA approval, NHS coverage, cardiovascular disease prevention Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai This content was created in partnership and with the help of Artificial Intelligence AI.